Kraig Biocraft Laboratories, INC 10-Q quarterly reports

Kraig Biocraft Laboratories, Inc. filed its Q2 2026 10-Q, revealing continued net losses and a substantial working capital deficiency, raising concerns about its ability to continue as a going concern.

Kraig Biocraft Laboratories, Inc. reported a net loss of $2.84 million for the nine months ended September 30, 2025, while increasing cash reserves through a standby equity purchase agreement.

Kraig Biocraft Laboratories, Inc. reported a significantly reduced net loss for the second quarter of 2025, driven by lower operating expenses and a capital raise, despite ongoing going concern doubts.

Kraig Biocraft Laboratories reports ongoing losses in Q1 2025, emphasizing the need for additional capital to sustain operations and execute its business plan.

Kraig Biocraft Laboratories reported no revenue for the third quarter of 2024, with a net loss of $433,200, while continuing to focus on research and development and scaling production of its spider silk technology.

Kraig Biocraft Laboratories reported a net loss of $2.11 million for the six months ended June 30, 2024, as operating expenses significantly increased.

Kraig Biocraft Laboratories reported a net loss of $507,875 for the first quarter of 2024, as the company continues to focus on research and development and production improvements.